- Magenta Therapeutics Inc MGTA shared preliminary data from the Phase 1/2 dose-escalation trial of MGTA-117 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts.
- The data comes from a Cohort 1, evaluating the lowest dose of MGTA-117 (0.02 mg/kg). Three patients completed the safety evaluation period.
- A fourth patient with a high disease burden did not complete the evaluation period due to disease progression with no drug-related adverse events.
- Related: Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial.
- MGTA-117 was shown to bind CD117+ cells in the blood in all four patients.
- One patient had measurable reductions of CD117+ erythroid progenitor cells in the bone marrow following MGTA-117 administration.
- An additional patient had an approximate 83% reduction of blasts in the bone marrow at day 14 post-dosing (from 6% to 1%). The patient proceeded to a conditioning regimen followed by a stem cell transplant.
- MGTA-117 was deemed to be cleared 48 hours after dosing in all four patients, a necessary step before stem cell infusion.
- For all four patients, no unexpected or severe drug-related adverse events, dose-limiting toxicities were observed, and drug-related adverse events higher were mild.
- Cohort 2 is now open and enrolling to evaluate MGTA-117 as a single dose of 0.04 mg/kg.
- Magenta ended Q1 2022 with approximately $156.6 million in the cash balance, expected to fund the operating plan into Q2 2024.
- Price Action: MGTA shares are down 3.51% at $1.10 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
